Sionna Therapeutics, INC S-1 registration statements
Registration statements, filed ahead of a public offering, with the business description and financials a first-time investor sees.
NASDAQ
Sionna Therapeutics files a Form S-1 to register an additional 2,029,409 shares of common stock, including those for underwriters' over-allotment option, after its initial S-1 was declared effective.
NASDAQ
Sionna Therapeutics, a clinical-stage biopharmaceutical company, has filed for an initial public offering to advance its novel medicines targeting the NBD1 domain of the CFTR protein for cystic fibrosis treatment.
NASDAQ
Sionna Therapeutics, a clinical-stage biopharmaceutical company, has filed an S-1 registration statement for an initial public offering to fund the development of novel medicines for cystic fibrosis.